These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 28674866

  • 41. Neurogenic orthostatic hypotension with critical illness neuropathy treated with droxidopa.
    Allen BB, Charles JA, Papadopoulos E, Avila EK.
    Auton Neurosci; 2016 Jul; 198():8-9. PubMed ID: 27423298
    [No Abstract] [Full Text] [Related]

  • 42. Neurogenic Orthostatic Hypotension: An Underrecognized Complication of Parkinson Disease.
    Sin MK, Khemani P.
    J Neurosci Nurs; 2020 Oct; 52(5):230-233. PubMed ID: 32649380
    [Abstract] [Full Text] [Related]

  • 43. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.
    J Parkinsons Dis; 2016 Oct 19; 6(4):751-759. PubMed ID: 27636856
    [Abstract] [Full Text] [Related]

  • 44. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 45. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    François C, Rowse GJ, Hewitt LA, Vo P, Hauser RA.
    BMC Neurol; 2016 Aug 18; 16(1):143. PubMed ID: 27538531
    [Abstract] [Full Text] [Related]

  • 46. [Postprandial hypotension.syncope in Shy-Drager syndrome and its treatment with oral L-DOPS].
    Hasegawa Y, Koike Y, Matsuoka Y, Takahashi A.
    Nihon Naika Gakkai Zasshi; 1989 Jul 18; 78(7):939-43. PubMed ID: 2507719
    [No Abstract] [Full Text] [Related]

  • 47. Prevalence of orthostatic hypotension in Parkinson's disease.
    Senard JM, Raï S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, Montastruc JL.
    J Neurol Neurosurg Psychiatry; 1997 Nov 18; 63(5):584-9. PubMed ID: 9408097
    [Abstract] [Full Text] [Related]

  • 48. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H.
    Clin Auton Res; 2008 Mar 18; 18 Suppl 1():19-24. PubMed ID: 18368303
    [Abstract] [Full Text] [Related]

  • 49. Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic?
    Merola A, Romagnolo A, Rosso M, Lopez-Castellanos JR, Wissel BD, Larkin S, Bernardini A, Zibetti M, Maule S, Lopiano L, Espay AJ.
    Parkinsonism Relat Disord; 2016 Dec 18; 33():65-71. PubMed ID: 27641792
    [Abstract] [Full Text] [Related]

  • 50. L-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy.
    Gibbons CH, Vernino SA, Kaufmann H, Freeman R.
    Neurology; 2005 Oct 11; 65(7):1104-6. PubMed ID: 16217067
    [Abstract] [Full Text] [Related]

  • 51. Droxidopa approved for neurogenic orthostatic hypotension.
    Traynor K.
    Am J Health Syst Pharm; 2014 Apr 01; 71(7):520. PubMed ID: 24644107
    [No Abstract] [Full Text] [Related]

  • 52. Orthostatic hypotension: pathophysiology, assessment, treatment and the paradox of supine hypertension.
    Chisholm P, Anpalahan M.
    Intern Med J; 2017 Apr 01; 47(4):370-379. PubMed ID: 27389479
    [Abstract] [Full Text] [Related]

  • 53. [Pharmaceutical care for Parkinson's patients with orthostatic dysregulation].
    Schulte S, Annicotte I, Mowitz A, Zerres M, Braun U, Joeres U, Jaehde R.
    Med Monatsschr Pharm; 2011 Jul 01; 34(7):250-6. PubMed ID: 21809600
    [No Abstract] [Full Text] [Related]

  • 54. Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension.
    Eisenhofer G, Goldstein DS.
    Clin Auton Res; 2021 Jun 01; 31(3):351-353. PubMed ID: 33977339
    [No Abstract] [Full Text] [Related]

  • 55. Ambulatory 24-hour blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone.
    Hakamäki T, Rajala T, Lehtonen A.
    Int J Clin Pharmacol Ther; 1998 Jul 01; 36(7):367-9. PubMed ID: 9707350
    [Abstract] [Full Text] [Related]

  • 56. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
    Sakoda S, Suzuki T, Higa S, Ueji M, Kishimoto S, Matsumoto M, Yoneda S.
    Eur Neurol; 1985 Jul 01; 24(5):330-4. PubMed ID: 3932074
    [Abstract] [Full Text] [Related]

  • 57. Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome.
    Ruzieh M, Dasa O, Pacenta A, Karabin B, Grubb B.
    Am J Ther; 2017 Jul 01; 24(2):e157-e161. PubMed ID: 27563801
    [Abstract] [Full Text] [Related]

  • 58. Benign paroxysmal positional vertigo in Parkinson's disease.
    Aranke SV, Sethi KD.
    Neurology; 2003 Oct 28; 61(8):1156. PubMed ID: 14581695
    [No Abstract] [Full Text] [Related]

  • 59. Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review.
    McDonell KE, Shibao CA, Biaggioni I, Hartman A, Robertson D, Claassen DO.
    Cogn Behav Neurol; 2019 Sep 28; 32(3):179-184. PubMed ID: 31517701
    [Abstract] [Full Text] [Related]

  • 60. Management of Orthostatic Hypotension.
    Palma JA, Kaufmann H.
    Continuum (Minneap Minn); 2020 Feb 28; 26(1):154-177. PubMed ID: 31996627
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.